1,194 search results for “anti-cancer drug steen” in the Public website
-
Laura Heitman appointed as Professor of Molecular Pharmacology
As of 1 November, Laura Heitman has been appointed full Professor of Molecular Pharmacology at the Leiden Academic Centre for Drug Research (LACDR). Heitman has been working on the understanding and improvement of drug-receptor interactions in early drug discovery. ‘My ultimate aim is to make medicines…
-
Seven Leiden researchers win €1.5m Vici grant
Seven Leiden researchers have each been awarded a Vici grant by the Netherlands Organisation for Scientific Research (NWO). This will enable them to form a research group and develop their own innovative line of research.
-
Education
Our educational programmes span the entire spectrum of pharmaceutical education, from training of the next generation drug researchers in the areas of drug design, drug action, and drug use to educating the pharmacists of the future.
-
Research
Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…
-
History
Life Sciences Artificial Intelligence Data Science
-
New resource for the modelling community
The Repository from the Drug Disease Model Resources (DDMoRe) consortium provides a home to a collection of computational models of disease and drug action that have been used in pharmaceutical and/or academic research. This publically available open-access resource will make it easier for researchers…
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.
-
Bio-Pharmaceutical Sciences (BSc)
As a student of Bio-Pharmaceutical Sciences, you have a strong interest in drug development: from the onset of diseases to the effects of individual drugs in the body. Is that true for you? Then, Bio-Pharmaceutical Sciences might be the right study programme for you!
-
Cannabinoid receptor 2 as a ‘drugable’ target: kinetic profile of novel receptor ligands
Supervisor: Andrea Martella
-
Novel analytical approaches to characterize particles in biopharmaceuticals
Particles are omnipresent in biopharmaceutical products. In protein-based therapeutics such particles are generally associated with impurities, either derived from the drug product itself (e.g. protein aggregates), or from extrinsic contaminations (e.g. cellulose fibers).
-
Programme structure
The Drug Discovery and Safety specialisation consists of compulsory and optional components.
-
Precision modeling of breast cancer in the CRISPR era
The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)genetic alterations in so-called driver genes.
-
Laura Heitman nominated for Prix Galien
Laura Heitman of the Leiden Academic Center for Drug Research (LACDR) has been nominated for the Prix Galien Research Award. This important pharmaceutical prize honors young, prominent researchers whose scientific research is of great importance for fundamental or clinical drug research.
-
NMR studies of protein-small molecule and protein-peptide interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal
-
Robert Rissmann appointed professor of Translational Dermatology at LACDR-CHDR
Pharmacist-clinical pharmacologist Robert Rissmann has been appointed Professor of Translational Dermatology. This extraordinary professorship has been created jointly by the Leiden Academic Centre for Drug Research (LACDR) and the Centre for Human Drug Research (CHDR) to strengthen their partnership…
-
Cancer cells: A closer look
What distinguishes a tumour cell from a healthy cell? Researchers are trying to answer this question as precisely as possible. Certain differences could eventually lead to new therapies.
-
Steffen Brünle
Science
-
LED3 Lecture: Molecular glues in drug discovery
Lecture
-
Prediction of human gut (colon cancer) target site concentrations and PKPD relationships
The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.
-
Key publications
Key publications of the Antiviral Pharmacology group.
-
Imaging functional brain connectivity: pharmacological modulation, aging and Alzheimer's disease
Psychologist Bernadet Klaassens initiated a large fMRI study on the effect of drugs on brain networks in aging and Alzheimer's disease. It generated a unique data set and insight into a new method to develop drugs for patients with Alzheimer's.
-
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474, SCIENCE, 2017
The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered…
-
NACTAR: The lugdunomycins: a new class of polyketide antibiotics with unique chemical scaffold
Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.
-
Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome
Fungal infections pose a significant threat to individuals with compromised immune systems and despite advancements in diagnosis and treatment, they continue to jeopardize patient’s health.
-
Quantitative pharmacology of antimicrobials
Antimicrobial drugs constitute a fundamental part of modern medicine. The global rise in antimicrobial resistance poses a major threat to global health.
-
Exploration of the endocannabinoid system using metabolomics
To increase clinical success rate of drugs, a better understanding of drug action mechanism and disease dynamics is required. Metabolomics, which studies small molecules involved in biochemical processes in organisms, has shown to be a useful tool for this better understanding.
-
Amphiphilic miktoarm star copolymers
Within this project, PeptoMiktoStars were realized through an orthogonal protecting group strategy and should be investigated further regarding their potential as drug delivery systems in the field of drug delivery to inflamed areas in cancer, bacterial infections or autoimmune diseases.
-
First-pass and systemic metabolism of cytochrome P450 3A substrates in neonates, infants, and children
Growth and development affect the metabolism of drugs administered to neonates, infants, and children.
-
Previous Winners
On this page you can learn more about the history of our Faculty Awards and view the previous winners.
-
Personalized drug repositioning using gene expression
PhD defence
-
Hit and Lead Optimization
The goal of hit and lead optimization is to optimize suitable chemical starting points that can modulate a drug target. The methods and technologies used are similar to those in Hit Discovery, but once the compound has shown activity in an animal model, it moves from 'hit' to 'lead.'
-
Symposium Transformations of the Audible / 16-18 May 2019
Sonorous phenomena are always on the verge of becoming something else. As it unfolds, sound constitutes spaces, mediates presence, articulates time. Furthermore, it may prompt emotions, generate awareness, organise patterns of behaviour or trigger a sense of belonging. As sound becomes audible, it is…
-
Information activities
Get to know us through our online and in-person events for prospective students!
-
Partner Institutes
The IBL represents the core of modern biological research at Leiden and we interact closely with the other life science Partner Institutes in the faculty:
-
Physicochemical analysis of allosteric binding pockets
Supervisor: Gerard van Westen
-
Using AI to improve the Design-Make-Test cycle with Galapagos
Researchers at LED3 are working together with biopharmaceutical company Galapagos to develop software for use in early drug discovery (funded by NWO). This software is able to design molecules with several simultaneously optimized characteristics and will also take prediction reliability into consideration…
-
Covalent inhibitors of G protein-coupled receptors: the case of adenosine receptors
Supervisor: Xue Yang
-
Polypept(o)ide-based nanostructures for therapeutic and diagnostic application
Nanoparticles exhibit a number of adjustable properties, e.g., their size, shape, and surface and core chemistry, which can be further diversified with different functional moieties. This opens a broad field for application in diagnostic and therapy. In this respect, the use of a polymeric hybrid material,…
-
Two-pronged attack on infectious diseases
A combination of two potential drugs gives hope of a 'super blockage' of an over-active immune system, Leiden researchers report in Nature. The breakthrough came from the crystallisation of a membrane protein.
-
NWO grant for smart software that searches for new medicines
Gerard van Westen and his group, together with pharmaceutical company Galapagos, start on developing software that invents new effective molecules. They will receive an NWO LIFT grant of 280,000 euros, of which 63,000 euros will come from Galapagos. The company will also bring its expertise in biology,…
-
Cancer research focusing on quality of life
Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…
-
Matching medication to DNA leads to 30% fewer side effects
According to the LUMC, patients experience 30% fewer serious side effects when medication doses are tailored to their DNA.
-
Staphylomics: Identifying host factors involved in staphylococcal infection
How can Staphylococcus aureus bacteria subvert the host immune system?
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
PhD defence
-
Tailor-made medicines
More and more medicines are becoming available that target a tumour’s specific traits. The use of chemotherapy is continually undergoing improvement.
-
AiChemist project
The AiChemist project (https://aichemist.eu) coordinated by Helmholtz Munich is an Innovative Doctoral Training Network funded through the Marie Skłodowska-Curie Actions (MSCA-DN) within the EU Horizon Research Framework, to the sum of €3 million. It brings together leading experts in AI, chemoinformatics…
-
Binding kinetics
A tantalizing concept that has emerged in our recent research is binding kinetics. An important parameter is residence time (RT), a direct reflection of how long a drug stays bound to its target. This parameter is of crucial importance, because drug action lasts only as long as the receptor-ligand complex…
-
About the program
In 2020, Leiden University launched its stimulated interdisciplinary programs, including one focused on regenerative medicine.
-
Regulation of nanoparticle biodistribution by scavenger endothelial cells (SECs)
A very large part of intravenously administered nanoparticles are cleared through the liver. Within the liver, most nanoparticles are thought to be sequestered by macrophages (Kupffer cells). To achieve effective cell-specific targeting of drugs and non-viral gene delivery vectors, improved mechanistic…
-
Development of novel metabolomics & systems pharmacology concepts to realize personalized medicine
The predication of the effect (efficiency and toxicity) of a drug in a patient is very important in (i) clinical decision support and (ii) the development of novel drug treatments.